EGFR and neoplasm: MK2206, as well as PI3K inhibitors, have been shown to act synergistically to improve anti-tumor activity in combination with EGFR TKIs in both the KRAS/EGFR WT and EGFR M+ NSCLC setting [30, 33, 34].